A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart

Urologic Consultants of Southeastern PA50 enrolled

Overview

Hypothesis: Dutasteride will perform better than finasteride in decreasing prostate volume, improving symptoms based on International Prostate Symptom score,and lower pvr based on the scientific information that dutasteride inhibits both Type I and II 5-alpha-reducatase vs. finasteride which only inhibits the Type II enzyme

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Benign Prostatic Hyperplasia

Interventions

DutasterideDRUG

0.5mg capsule, taken once daily for 12 months

Eligibility

Sex: MALEMin age: 50 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male * Age 50-80 * On finasteride for no less than 12 months * Willing to undergo all necessary test in the 12 month evaluation Exclusion Criteria: * History of medication non-compliance * Unwillingness to undergo/tolerate 2 blood draws * Unwillingness to tolerate/undergo 2 TRUSP

Locations (1)

Urologic Consultants of Southeastern PA

Bala-Cynwyd, Pennsylvania, United States

Outcomes

Primary Outcomes

Laboratory parameters: including serum testosterone, DHT level and PSA

Time frame: 12 months

Secondary Outcomes

volume measurements of TRUSP and PVR

Time frame: 12 months

A decrease in the AUASI

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.